PD15-13: Evaluating the Effect of Prior Checkpoint Inhibitor Exposure on Outcomes with Enfortumab Vedotin and Pembrolizumab in First Line Metastatic Bladder Cancer: A Retrospective Cohort Study

PD15-13: Evaluating the Effect of Prior Checkpoint Inhibitor Exposure on Outcomes with Enfortumab Vedotin and Pembrolizumab in First Line Metastatic Bladder Cancer: A Retrospective Cohort Study

Saturday, May 16, 2026 4:58 PM to 5:06 PM · 8 min. (America/New_York)

206

Abstract

Speakers

Residentyale school of medicine

Sessions

Saturday, May 16, 2026 3:30 PM to 5:30 PM

Stanley Malkowicz · university of pennsylvania

Log in

See all the content and easy-to-use features by logging in or registering!